Five polymorphisms and breast cancer risk: Results from the breast cancer association consortium

Grants

Funding Acknowledgements

We thank all the participants for taking part in this research. The MCCS is supported by the Australian National Health and Medical Research Council (grants 209057, 251533, 396414, 504711). Cohort recruitment and follow up is funded by The Cancer Council Victoria. The MCBCS was supported by the National Institutes of Health grant and the U.S. medical research and materiel command breast cancer IDEA award W81XWH-04-1-0588. ELG is a Fraternal Order of the Eagles Cancer Research Fellow. The MARIE study is supported by the Deutsche Krebshilfe e.V. (Project number 70-2892-Br 1). We thank Tracy Slanger and Elke Mutschelknauss for supervision of patient recruitment and clinical data collection and Ursula Eilber, Sabine Behrens, Nicole Knese-Yanning, and Belinda Kaspereit for excellent technical support. The KBCP was supported by the special Government Funding (EVO) of Kuopio University Hospital grants, Finnish Cancer Organisations and Cancer Fund of North Savo. We are grateful to Eija Myohanen for technical assistance. The KARBAC was supported by the Swedish Cancer Society, the Gustav the V Jubilee Foundation, the FoU Foundation and the Bert von Kantzows Foundation. The HEBCS was supported by The Academy of Finland (project 110663), Helsinki University Central Hospital Research Funds, The Sigrid Juselius Foundation and The Finnish Cancer Society. We thank Drs. Carl Blomqvist and Kristiina Aittomoki and Research Nurse Kirsi Leinonen for help with patient contacts and data collection. The HABCS was supported by an intramural grant of Hannover Medical School. NB was generously supported by the Friends of Hannover Medical School. We gratefully acknowledge the technical assistance of Marion Haidukiewicz in DNA sample preparation. We furthermore thank Peter Hillemanns, Christof Sohn, Alexander Scharf, Michael Bremer and Johann Hinrich Karstens for their invaluable support in terms of infrastructure and patient samples. The GC-HBOC study was supported by Deutsche Krebshilfe (107054), by the Center of Molecular Medicine, Cologne, and the Helmholtz society. We are thankful to Bernd Frank for participating in genotyping. The GENICA study was supported by the German Human Genome Project and funded by the Federal Ministry of Education and Research (BMBF) Germany grants 01KW9975/5, 01KW9976/8, 01KW9977/0 and 01KW0114. Genotyping analyses were supported by Deutsches Krebsforschungszentrum, Heidelberg and the Robert Bosch Foundation of Medical Research, Stuttgart, Germany. Yon Ko was involved in the design of the GENICA study and was responsible for patient recruitment and collection of clinical data. Beate Pesch and Thomas Bruning were involved in the design of the GENICA study and responsible for recruitment of the study subjects as well as collection of epidemiological data. The CNIO-BCS was supported by the Genome Spain Foundation. We thank Anna Gonzalez-Neira, Charo Alonso and Tais Moreno for their technical support. The CGPS was supported by Chief Physician Johan Boserup and Lise Boserup Fund, the Danish Medical Research Council and Copenhagen County. The BBCS and the Mammography Oestrogens and Growth Factors study are funded by CR-UK and Breakthrough Breast Cancer. Funding of the ABCS study was provided by the Dutch Cancer Society (grants NKI 2001-2423; 2007-3839) and the Dutch National Genomics Initiative. ABCS acknowledges Richard van Hien, Linde Braaf, Rob Tollenaar and other contributors to the 'BOSOM' study, and the support of dr. H.B. Bueno-de-Mesquita for organizing the release of control DNA. The ABCFS was funded by the National Health and Mdical Research Council, the Victorian Health Promotion Foundation, the New South Wales Cancer Council, and as part of the Breast Cancer Family Registry funded by the National Cancer Institute (USA) under RFA #CA-95-003. We want to thank Letitia Smith for her contribution to the genotyping for ABCFS. John Hopper is an Australia Fellow of the National Health and Medical Research Council (NHMRC) and Melissa Southey is a NHMRC Senior Research Fellow. From the University of Southern California, we thank Loreall Pooler and David Wong for their laboratory assistance for the MEC study. The MEC Study was supported by National Cancer Institute (NCI) grants CA63464 and CA54281. NHS acknowledges acknowledge Pati Soule and Hardeep Ranu of the DF/HCC High Throughput Polymorphism Detection Core. NHS was supported by NCT grants CA 0657245 and CA098233. The ORIGO study was funded by the Dutch Cancer Society; we thank Jannet Blom, Elly Krol-Warmerdam, and Petra Huijts for patient recruitment and collection of clinical data. The PBCS was funded by Intramural Research Funds of the National Cancer Institute, Department of Health and Human Services, USA. The authors would like to thank Dr. Neonila Szeszenia-Dabrowska of the Nofer Institute of Occupational Medicine (Lodz, Poland) and Witold Zatonski of the M.Sklodowska-Curie Institute of Oncology and Cancer Center (Warsaw, Poland) for their contribution to the PBCS. The SASBAC study was supported by funding from the Agency for Science, Technology and Research of Singapore (A*STAR), the United States National Institute of Health (NIH) and the Susan G. Komen Breast Cancer Foundation. The SBCS was supported by Yorkshire Cancer Research and the Breast Cancer Campaign. We would like to thank Sue Higham, Helen Cramp, Dan Conriley, Ian Brock, Gordon MacPherson, Nitai Bhattacharyya and Mark Meuth for their contribution to the SBCS. SEARCH was funded by Cancer Research-UK (CR-UK); contributing authors, PDPP is a Senior Clinical Research Fellow. The SEBCS was supported by a grant from the National Research and Development Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (0620410-1). The TWBCS was supported by the Department of Health, Taiwan. UCIBCS is Supported by grants from the NCI (CA2 R01 CA58860-14) and the Lon v smith Foundation (LVSF-41027, 3834, 42344). The USRT Study was supported in part by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Inistutes of Health, USA. The authors are grateful to the radiologic technologists who participated in the USRT Study; Jerry Reid of the American Registry of Radiologic Technologists for continued support of this study; Diane Kampa and Allison Iwan of the University of Minnesota for data collection and study coordination; Chris McClure of Research Triangle International, Inc. for tracing and data management; and, Laura Bowen of Information Management Services for biomedical computing. For the UBCS, genotype data and analysis Was Supported by a Susan G. Komen Foundation grant (BCTR0706911) and an NIH grant (CA98364). Data collection was supported by NCI, assisted by the Utah Cancer Registry, which is funded by contract number N01-PC-35141 with additional support from the Utah State Department of Health and the University of Utah. Partial Support for all datasets with the Utah Population Database was provided by the University of Utah Huntsman Cancer Institute. The authors are grateful to Study Coordinators, Laboratory Specialst Kim Nguyen, and Computer Specialist Jathine Wong. We wish to thank Heather Thorne, Eveline Niedermayr, all the kConFab research nurses and staff, the heads and staff of the Family Cancer Clinics, and the Clinical Follow Up Study (funded by NHMRC grants 145684, 288704 and 454508) for their contributions to this resource, and the many families who contribute to kConFab. kConFab is supported by grants from the National Breast Cancer Foundation, the National Health and Medical Research Council (NHMRC) and by the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia. ACS/AOCS: The AOCS Management Group (D Bowtell, G Chenevix-Trench, A deFazio, D Gertig, A Green, P Webb) gratefully acknowledges the contribution of all the clinical and scientific collaborators (see http://www.aocstudy.org/), AOCS and the ACS Management Group (A Green, P Parsons, N Hayward, P Webb, D Whiteman) thank all of the project staff, collaborating institutions and Study participants. Financial support was provided by: U.S. Army Medical Research and Materiel Command under DAMD17-01-1-0729, the Cancer Council Tasmania and Cancer Foundation of Western Australia (AOCS study); The National Health and Medical Research Council of Australia (199600) (ACS study). The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centres in the CFRs, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government or the CFRs Centers. The genotyping and analysis were supported by grants from the National Health and Medical Research Council (NHMRC). ABS was funded by an NHMRC Career Development Award, and GC-T and JLH are NHMRC Senior Principal Research Fellows.